ARTV

#2865
Artiva Biotherapeutics, Inc. - Common Stock
11.2 8 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
11.19
11.29
Intervallo Annuale
4.07
14.53
Variazione giornaliera
+1.71%
Variazione Mensile
+12.80%
Variazione di 6 mesi
+106.22%
Variazione Annuale
+171.15%
Chiusura Precedente
11.0 9
Open
11.2 3
Minimo
11.1 9
Massimo
11.2 9
Volume
71
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K

Artiva Biotherapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Artiva Biotherapeutics, Inc. (ARTV) covers events occurring on May 18, 2026. The filing details significant changes to the Company's executive leadership and Board of Directors, including the resignation of a director, the departure of the Chief Financial Officer, and the appointment of new officers.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. However, it discloses specific compensation and severance figures related to the personnel changes:

  • Severance to Departing CFO: Thad Huston is eligible for a cash payment of approximately $135,000 (three months' base salary) and up to nine months of COBRA health coverage, contingent on signing a separation agreement.
  • New Executive Compensation: Dr. Diego Miralles, appointed President and Head of R&D, will receive an annual base salary of $600,000 and a discretionary annual cash bonus with a target of 45% of base salary.
  • Equity Grants: Dr. Miralles received an inducement award of 232,500 stock options and 77,500 restricted stock units (RSUs), vesting over four years.

Material Changes Versus Prior Period

The primary material changes reported are structural and personnel-related rather than financial performance shifts:

  • Board Composition: The Board size was reduced from eight to seven members following the resignation of Dr. Diego Miralles as a director.
  • Executive Roles:
    • Dr. Fred Aslan resigned as President but remains CEO and was appointed Principal Financial and Accounting Officer.
    • Dr. Diego Miralles resigned as a Director to become President and Head of Research and Development.
    • Thad Huston departed as Chief Financial Officer, effective May 22, 2026.
  • Consulting Agreements: A consulting agreement with Dr. Miralles regarding clinical and regulatory strategy, entered in April 2026, was terminated on May 17, 2026, in connection with his new employment.

Guidance, Outlook, and Risks

The filing does not contain updated financial guidance or operational outlook. Key contingencies and risks identified include:

  • Leadership Transition: The Company is conducting a search for a replacement for the departing CFO.
  • Severance Contingencies: Severance payments to Dr. Miralles (ranging from 3 to 12 months of salary depending on termination cause and timing relative to a Change of Control) and Mr. Huston are conditional upon the execution of separation agreements and releases of claims.
  • Equity Vesting: Future compensation for Dr. Miralles is tied to continued employment and specific vesting schedules for options and RSUs.

Investor Verification Checklist

  • Verify the status of the search for a permanent Chief Financial Officer replacement.
  • Review the filed Separation Agreement with Thad Huston and the Offer Letter with Dr. Miralles (Exhibits) for full terms of severance and equity vesting.
  • Confirm the impact of the CFO departure on the timing of future financial reporting and audit processes.
  • Monitor the Board's composition and any potential need to fill the vacant director seat.